VION Biosciences (Iron Path Capital) /
Prolytix
Iron Path Capital-backed VION Biosciences closed the acquisition of Prolytix from Edgewater Capital Partners on Sep 8.
- Terms
- Undisclosed
- Stage
- Closed
- Seller
- Edgewater Capital Partners
What happened
Terms were undisclosed. CEO Mark Thornton said the deal deepens VION in regulated large molecule bioanalytical and CMC services plus reagents, consumables, and diagnostic workflow inputs.
Prolytix brings regulated bioanalytical and CMC services, research reagents, and custom sample collection products for biopharma and diagnostics customers. It is VION's sixth acquisition since 2023, building on the platform that already includes CTL and Ansh Labs.
Who bought Prolytix?
VION Biosciences (Iron Path Capital) acquired Prolytix from Edgewater Capital Partners (Closed, posted 13 Sep 2026).
The source
Iron Path Capital-backed VION Biosciences closed the acquisition of Prolytix from Edgewater Capital Partners on Sep 8.
Original filingUnlock with ProTimeline
Closed
Published by the source
Deal Web
Every firm and person on this deal, and how they connect. Open any name to see their other deals.
Closed · VION Biosciences (Iron Path Capital) acquired Prolytix from Edgewater Capital Partners (Closed, posted 13 Sep 2026).
Closed 8 Sep 2026- Closed
- Posted on @carrywatch
Deal Web as a list
- VION Biosciences (Buyer) acquired this deal. VION Biosciences: 1 deal on Carrywatch.
- Iron Path Capital (Backer of the buyer) backed this deal. Iron Path Capital: 1 deal on Carrywatch.
- Prolytix (Target) target this deal. Prolytix: 1 deal on Carrywatch.
- Edgewater Capital Partners (Seller) sold this deal. Edgewater Capital Partners: 1 deal on Carrywatch.
- Mark Thornton (CEO) named in post this deal. Mark Thornton: named in 1 post on Carrywatch.
Mark Thornton
CEO
By email · Weekly